Opinion|Videos|April 1, 2025
Building Better Collaboration: Reducing Care Delays in Managing mCRC
Experts discuss proactive steps health care teams, including pharmacists, can take to minimize delays and overcome payer-related barriers when prescribing third-line therapies for metastatic colorectal cancer (mCRC) and how collaboration between health care teams, payers, and manufacturers can be improved to reduce care delays.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What proactive steps can health care teams, including pharmacists, take to minimize delays and overcome payer-related barriers when prescribing third-line therapies?
- How can collaboration between health care teams, payers, and manufacturers be improved to reduce delays in care for patients with mCRC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
5 Things to Know About the Oral GLP-1 Era
5
